HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Neutrogena Introduces Helioplex Sun Care, Cleansing Pads

This article was originally published in The Rose Sheet

  • News
  • Stephanie Jones

Executive Summary

Neutrogena Helioplex sun care, formulated with stabilized avobenzone, "blocks more UVA rays than the leading sunscreens available in the U.S.," Johnson & Johnson claims

You may also be interested in...



Sun Defense Is Common Denominator In Neutrogena’s Product Fleet For 2007

Neutrogena's new product lineup for 2007 focuses on sun protection, comprising a quintet of innovative sun blocks as well as cosmetics fortified with their own levels of SPF

Sun Defense Is Common Denominator In Neutrogena’s Product Fleet For 2007

Neutrogena's new product lineup for 2007 focuses on sun protection, comprising a quintet of innovative sun blocks as well as cosmetics fortified with their own levels of SPF

Neutrogena Battery-Powered Microderm System Among New Launches

Neutrogena Advanced Solutions At Home MicroDermabrasion System immediately enhances surface cell turnover to improve skin clarity in one week, according to the Johnson & Johnson division

Table

View full table

Related Content

HBW Insight
Tags:
Latest Headlines

Swisse Supplements Take Bigger Slice Of Chinese Market

There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable

US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade

Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024

See All
UsernamePublicRestriction

Register

RS013627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By